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Infectionswith protozoans ofthe family Trypanosomatidae cause several wide-
spread human disorders including Chagas disease and various forms ofleishman-
iasis (1). Patients with Chagas disease develop antibodies reacting with blood
vessels, endocardium, striated muscle, and peripheral nerves (2-6) and these
antibodies are thoughtto beinvolvedin thedevelopmentofdegenerative changes
in various organs in these patients (7). Laminin, a large glycoprotein found
exclusively in basement membranes (8) was able to bind most of the tissue-
reacting antibodies present in these sera (6). Similar laminin-reacting antibodies
have been detected in patients with American cutaneous and mucocutaneous
leishmaniasis (9) and with poststreptococcal glomerulonephritis (10). However,
these antibodies have been found to crossreact with various forms ofthe parasites
(2, 3, 6, 11), as well as with animal erythrocytes (3, 11-13) and structurally
distinct basement membrane proteins such as laminin and nidogen (13). A similar
but unexpected crossreaction was observed between rat neurones and Trypano-
some cruzi using an mAb (14). These tissue-reacting antibodies may, however,
not have a key role in invoking protective immunity against trypanosomal
infections (15).
Since distinct proteins contained the epitope, it seemed likely that it was not
these proteins themselves but rather a common posttranslational modification
that was the actual reactant (13). Additionally, such epitopes could exist in
sufficient amounts in human tissue to explain the occurrence ofthese antibodies
and suggest a possible pathogenetic role of such antibodies in these disorders
(11, 16). These antibodies show distinct reactions with epitopes present in rodent
and other animal tissues (6, 11, 12, 16). Initial observations on binding to human
tissues in situ and in vitro (2, 3) have been revised recently (12), and indicate
Thestudy was in part supported by grants of theDeutsche Forschungsgemeinschaft (project Ti 95/6-
2), and of CONICIT, Venezuela. Address correspondence to R. Timpl, Max-Planck-Institut fur
Biochemie, D-8033 Martinsried, Federal Republic of Germany.
Journal of Experimental Medicine - Volume 166, August 1987
￿
419-432
￿
419420
￿
ANTIBODIES TO MOUSE LAMININ IN CHAGAS DISEASE
that the tissue-reacting antibodies are generated due to a lack of immune
tolerance for these epitopes in the human species.
In this study, we provide evidence for the carbohydrate nature of epitopes of
mouse laminin that react with antibodies in the sera of leishmaniasis and chagasic
patients, as well as in infected monkeys. The structure responsible for this
interaction appears to be a terminal Galal-3Ga1 group on N-linked oligosaccha-
rides of mouse laminin. Surprisingly, an identical or very similar epitope is
recognized by normal human laminin-binding antibodies, which apparently cor-
respond to a-galactose-specific natural antibodies described in previous studies
(17-19). Additional data indicate that these structures may also be present in
some normal and pathological human tissues.
Materials and Methods
Serum Panels and Antisera.
￿
Sera with high-binding capacity for laminin were obtained
by screening sera from patients with American cutaneous leishmaniasis and chronic Chagas
disease as described previously (9, 13). Sera with similar high laminin binding were also
obtained from rhesus monkeys infected by the ocular route with T. cruzi trypomastigotes
(6) or inoculated intravenously with Trypanosoma rhodesiensetrypomastigotes (20). Normal
sera were collected in Germany from 8 female and 11 male volunteers (age range, 25-52
yr; average, 39 yr). The normal donors had normal values in several standard laboratory
tests and lacked exposure to the parasitic diseases studied here.
Rabbit antisera against native laminin were described in previous studies (8, 21). Human
blood group typing sera were obtained from Behringwerke AG, Marburg, Federal
Republic of Germany. A polyvalent antiserum against human Ig was prepared in a sheep
by repeated injections of Cohn fraction II serum protein mixed with CFA and was used
in most binding studies as secondary antibody. In some studies we used specific goat
antisera against human IgG, IgM, and IgA purchased from Medac, Hamburg, Federal
Republic of Germany.
Sources ofAntigens and Inhibitors.
￿
Laminin (8), nidogen, heparan sulfate proteoglycan
(22), and protein BM-40 (23) were purified from the mouse Engelbreth-Holm-Swarm
tumor. Laminin was also extracted with 10 mM EDTA containing buffer from human
placenta (24) and purified by chromatography on Sepharose Cl-6B and DEAF-cellulose
and was found to contain A, B, and M chains (25). Human plasma fibronectin was a kind
gift of Dr. H. Richter, Max-Planck-Institut Fur Biochemie, Martinsried, Federal Republic
of Germany. Laminin B chains were prepared from reduced and alkylated bovine
glomerular basement membranes (26) and were purified by ion exchange and molecular
sieve chromatography. Conditioned meda of various human cell lines were obtained by
incubatingconfluent cultures of the cells for 24 h in serum-free DMEM, provided by Dr.
M. Aumailley, Max-Planck-Institut Fur Biochemie. These materials were free of myco-
plasma contaminations. Human saliva was used as a source of blood group substances.
Glycosphingolipids from rabbit erythrocytes were extracted and separated into compo-
nents with short and long oligosaccharide chains (27). Various mono- and oligosaccharides
were obtained from Biocarb AB, Lund, Sweden, or Sigma Chemical Co., St. Louis, MO,
and originated from natural sources or were synthetic products.
Modifications ofLaminin and OtherAntigenic Substances.
￿
Complete reduction and alkyl-
ation of laminin in 6 M guanidine-HCI followed a previously used procedure (21). For
alkaline degradation, lyophilized laminin (3 mg/ml) was dissolved in 0.5 M NaOH, 0.1 M
sodium borohydride and the solution was neutralized with glacial acetic acid after 2 d
incubation at 37 °C. Laminin dissolved in 0.5 M NaCl, 0.05 M Tris/HCI, pH 7.4, was also
treated with pronase B (Sigma Chemical Co.) at an enzyme/substrate ratio of 1 :50 for 2
d at 37'C to remove protein segments. Before periodate treatment, the pH of the laminin
solution was lowered to 4.5, causing partial precipitation of the protein. After addition of
periodic acid (0.02 M) and incubation for 24 h at 4'C the protein was redissolved byTOWBIN ET AL.
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dialysis against 0.5 M NaCl, 0 .05 M Tris/HCI, pH 7 .4, and the extent of degradation was
measured by orcinol reaction (28).
Other samples of laminin were dialyzed against 0.5 M sodium acetate buffer, pH 5.0,
and treated for 20 h at 37°C with either a-galactosidase (20-35 U/mg) or 0-galactosidase
(10-15 U/mg), both from Aspergillus niger (Sigma Chemical Co.), using 1 U of enzyme
per 1 .5 mg of laminin. These treatments did not cause degradation of the polypeptide
chains of laminin, as judged from electrophoresis. Similar incubations were carried out
with O-N-acetylglucosaminidase (10 U/ml; from A. niger) and a-N-acetylgalactosaminidase
(2 U/ml, from Charonia lampas).
Chemical defucosylation (29) was achieved by heating antigens in 0.1 M TCA for 1 h
at 100°C. Antigens were then precipitated at 4°C with 2 volumes of acetone, washed
once with acetone, and dissolved in PBS, pH 7 .2 . Controls were heated without TCA and
processed as above.
Immunological Assays.
￿
Laminin was labeled with 1251 to a specific activity of 8,000-
12,000 cpm/ng by the chloramine T procedure and used at 2 ng/0.4 ml for direct binding
analysis after standard protocols (30). For radioimmuno-inhibition assays, appropriate
antiserum dilutions were incubated with nonlabeled inhibitors (24 h, 4° C) before the
addition of labeled antigen and binding analysis (30).
Dot binding assays followed the procedure of Hawkes et al. (31), with slight modifica-
tions. Protein solutions (1 j,l) were spotted onto nitrocellulose (Millipore, Molsheim,
France), briefly washed with water, fixed with 0.1 % glutaraldehyde/0.4% formaldehyde,
again washed with water and blocked with 0.1% BSA, 0 .05% Tween 20 in PBS (BTB)'
for 1 h at 37'C. The strips were incubated with sera diluted 1 :100-300 in BTB for 3 h
at room temperature. Peroxidase conjugates of second antibodies (goat anti-monkey Ig
from E.Y. Laboratories, Inc., San Mateo, CA; affinity-purified, polyvalent goat anti-
human IgG from Tago Inc ., Burlingame, CA) were used for incubations (1 h, room
temperature) at dilutions of 1 :500 . The glycosphingolipid blotting assay followed a
previous procedure (32), except that BTB was used as diluent and for blocking and
washing.
Results
Laminin Binding of Normal and Patient Sera and Sera from Infected Monkeys in
RIA. Sera from patients (n = 15-25) with American cutaneous and mucocuta-
neous leishmaniasis, with Chagas disease, as well as from monkeys infected either
with T. cruzi or T. rhodesiense and from normal human subjects were examined
for binding of 1251-labeled mouse laminin by a double antibody RIA. All sera
produced typical binding profiles with up to 50-60% of laminin bound at the
lowest serum dilution (1:100) examined (Fig. 1, a and b). The titers of antisera
were highest in the infected monkeys, followed by patient and normal sera.
However, three individuals among the normal control group (n = 19) showed
titers as high as those found in the patient group (Fig. 1a). Binding of laminin
was found to be mainly due to IgG rather than IgM or IgA antibodies, as
illustrated for a normal serum (Fig. 1 c). Asimilar prevalence ofIgG binding was
previously demonstrated (9, 13) for patient sera by enzyme immunoassays.
Specificity of the binding reaction was demonstrated by passing patient and
normal sera over columns containing immobilized laminin and observing that
binding was reduced to background levels (Fig. 1 b). The residual binding was
no longer dependent on serum concentration, indicating that it is probably due
to nonspecific adsorption oflabeled laminin to the test tubes. Adsorption ofsera
on nonsubstituted supporting material had no effect on laminin binding (Table
1 Abbreviations used in this paper:
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Comparison of RIA binding of mouse laminin by normal and leishmaniasis sera
(a), the effect of laminin immunoadsorption on binding (b), and identification of Ig classes
involved in binding by normal serum (c). The data in a show the average binding of serum
panels from normal volunteers (", n = 19)andpatients with American cutaneous leishmaniasis
(O, n = 15); vertical bars indicate the standard deviation. In addition, individual binding
profiles of two normal sera which show the strongest (") and weakest (") bindingactivity are
illustrated. Data in b show binding profiles before (open symbols) and after (closed symbols)
immunoadsorption on laminin of an individual normal serum (p,/) and patient serum (O,").
Data in c were obtained with an individual normal serum after precipitation of immune
complexes with antisera specific for either human IgG (A), IgA (p) or IgM (A).
TABLE I
Removal ofLaminin-binding Activityfrom Patient(LS) and Normal
(NS) Human Serum by Absorption with Erythrocytes
Equal volumes of serum (diluted 1:10) and of 50% erythrocyte suspen-
sion incubated over night at 4°C. Supernatants were diluted 1:10 or
1:20 for bindingtests.
* LS, leishmaniasis sera.
t NS, normal human sera.
§ No difference with A1, A2, B, or O blood group.
1). The binding of labeled laminin was also completely blocked by preincubation
of sera with soluble, nonlabeled laminin (Fig. 2a) with a 50% reduction achieved
at concentrations as low as 0.01-0.1 nM (0.01-0.1 ug/ml). These quantitative
inhibition assays were subsequently used in the elucidation of the structure of
epitopes involved in the reaction.
Nature of Laminin Epitopes Recognized by Patient and Monkey Antisera.
￿
A
comparison of various murine basement membrane proteins by inhibition assays
(Fig. 2a) demonstrated that other macromolecules, including nidogen and hep-
aran sulfate proteoglycan, were also able to completely block laminin binding.
Their activity was some 10-20% of laminin on a molar basis, indicating they
Absorption
Supernatant
LS*
binding of "'I-laminin
NS$
Buffer control 37 ± 5 42 ± 1
Sepharose 38 ± 3 42 ± 2
Laminin-Sepharose 5 ± 1 13 ± 1
Human erythrocytes§ 33 t 4 40 ± 2
Sheep erythrocytes 5 ± 1 16 ± I
Rabbit erythrocytes 4 ± 1 5 ± IFIGURE 2. Crossreaction of
laminin-binding leishmaniasis
antibodies with other base-
ment membrane proteins (a)
and stability of epitopes on
laminin against degradation
(b). Antigenic activity was de-
termined by radioimmuno-in-
hibition assay using 1251-la-
beled laminin andtwo individ-
ual patient sera. Inhibitors
used were laminin (40), hep-
aran sulfate proteoglycan (A),
nidogen (Q), protein BM-40
10-, 10-1 101 10' 102 10-1 10-' 101 10' 102 (A) reduced and alkylated
Inhibitor (nM)
￿
laminin (0), laminin B chains-
and laminin digests obtained after treatments with pronase (p), alkali (0), or periodate ("). All
antigens originated from a mouse tumor except the B chains, which were from bovine glomerular
basement membranes.
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FIGURE 3. Comparison by
radioimmuno-inhibition assay
of mouse laminin before and
after treatment with exogly-
cosidases (a and b) and cross-
reactivity of human laminin (a
and b) and conditioned cell
culture medium (c). The test
system consisted of 1251-la-
beled mouse laminin and a
normal serum (a)or leishman-
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￿
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￿
of the reactions in a and b
Inhibitor concentrations
￿
were
￿
mouse
￿
laminin
￿
(0),
human placenta laminin (0), mouselaminin aftertreatmentwith 0-galactosidase(A)or a-galactosidase
(A), and human plasma fibronectin (V). Culture media in c were obtained from human embryonic
fibroblasts (A), fibrosarcoma HT 1080 cells ("), astrocytoma cell line 251 MG (p), and rhadbdomy-
osarcoma cell line A 204 (A).
contained a lower content of epitopes or had a lower affinity for the antibody.
This interpretation was confirmed by inhibiting the reaction of the same anti-
serum with "'I-labeled nidogen (13), which revealed laminin to be a 5-10-fold
better competitor than nidogen and proteoglycan (data not shown). Another
small protein, BM-40 which contains only one to two carbohydrate side chains
(23), had a 1,000-fold lower inhibitory capacity than laminin (Fig. 2a). It is
possible that the low activity observed with BM-40 is due to contaminants rather
than theprotein itself. However, a strong crossreaction was observed with laminin
B chains obtained from bovine glomerular basement membranes (Fig. 2b).
Since these crossreactions with unrelated proteins indicated a possible glyco-
conjugate nature ofepitopes (13), laminin was subjected to various chemical and
enzymatic treatments. The digests were compared with intact laminin in inhibi-
tion assays (Figs. 2b and 3), demonstrating no loss of activity after complete
reduction of disulfide bonds and only a three- to fivefold loss after treatments
with pronase or alkali. Examination of the latter two digests by molecular sieve
chromatography demonstrated all of the laminin had been degraded to small
peptides. Conversely, periodate treatment, which reduced the carbohydrate424
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TABLE II
Inhibitory Activity ofMono- and Oligosaccharidesfor Laminin-binding by Leishmaniasis Sera
(LS), Normal Human Sera (NS), and Serumfrom Monkey Infected with T. cruzi (MS)
Saccharides
Concentrations of inhibitor (IAM) required for 50% inhibition*
* Determined by radioimmuno-inhibition assays.
content oflaminin by 70%, reduced its inhibitory activity to 2% of control (Fig.
2b). Inhibitory activity of the pronase and alkali digests of laminin were com-
pletely destroyed by periodate treatment. In contrast to these results, only the
periodate-treated laminin was able to inhibit rabbit antisera raised against native
laminin (data not shown), which are known to react with peptide epitopes (21).
The possible involvement of terminal sugar residues present at the nonreduc-
ing end of oligosaccharides in laminin was evaluated using specific exoglycosi-
dases. Treatment with a-galactosidase caused a 100-fold loss ofinhibitory capac-
ity- of laminin, while only a two- to threefold decrease was observed with #-
galactosidase (Fig. 3b). The latter effect can be presumably attributed to a small
contamination of a-galactosidase usually present in such enzyme preparations.
No substantial effects on antigenicity were observed after treatments with (3-N-
acetylglucosaminidase and a-N-acetylgalactosaminidase in dot binding assays
(data not shown) . This indicates that terminal a-galactose residues are part of
the carbohydrate epitopes on mouse laminin recognized by patient and monkey
antibodies.
Reaction of Antibodies with Defined Carbohydrate Structures.
￿
The presence of
terminal a-galactose groups on laminin was recognized in previous studies (33-
35) but their precise linkage to other galactose residues has so far not been
established (35). We have therefore used various mono- and oligosaccharides to
study the specificity ofepitope recognition by inhibition assays (Table II). Among
the various components tested Galal-3Gal and Galal-3Galf 1-3G1cNAc showed
the strongest activity in completely blocking the binding of laminin at concentra-
tions of 10-100 AM. A 105-fold molar excess of Galal-3Gal compared with
laminin is required to produce 50% inhibition (Table II), which corresponds to
a 300-fold difference compared on a carbohydrate weight basis. Other galactose
disaccharides that differ in a-glycosidic linkage (al-4 and al-6) were 100-
1,000-fold less competent inhibitors than Galal-3Gal. A lower activity was also
Mouse laminin
Gal al-3 Gal
LS 1
40 X 10-6
0.5
LS 15
32 x 10-6
0.6
NS 21
14 x 10-6
5.4
NS 25
30 X 10-6
8.9
MS
700 x 10-6
7.0
Gal al-6 Gal 81 2,400 1,400 40 >1,000
Gal al-4 Gal >1,500 >1,500 >1,500 >1,500 >1,500
GalaI-3(FucaI-2)Gal 300 30 78 630 >700
a-methyl galactose 400 5 X 106 400 200 >20 x 109
0-methyl galactose >20 x 109 >20 x 109 20 x 109 >20 x 109 >20 x 109
Galactose 11 x 10' lox 109 33 x 10' 1.5 x 109 >30 X 109
Glucose >55 x 10' >55 x 10' >55 x 10' >55 x 10' >55 x 10'
Mannose >55 X 10' >55 X 103 >55 X 10' >55 X 10' >55 X 10'
Gal NAc >45 x 10' >45 x 10' 40 X 10' >45 x 10' >45 x 10'
Glc NAc >45 x 10' >45 X 10' >45 x 10' >45 x 10' >45 x 10'TOWBIN ET AL.
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FIGURE 4 .
￿
Detection of a-galactose
epitopes on glycosphingolipids pre-
pared from rabbit erythrocytes . The
lipids were enriched by Folch's par-
tition for components with long (A)
and short (B) carbohydrate chains
(27). After separation by TLC and
blotting to nitrocellulose they were
reacted against two different leish-
maniasis patient sera (LS) ; three dif-
ferent normal human sera (NS) all
diluted 1:100, and against blood
group typing sera specific for A and
B blood group substances (dilution
1 :10). The arrow denotes the posi-
tion of a pentasaccharide ceramide
described by Stellner et al . (37) . The
slow migratingband in A, which also
reacts with anti-B antisera, may cor-
respond to a ceramide decasacchar-
ide describedby Hanfland et al . (38) .
Reaction patterns similar to LS sera
are observed at higher concentra-
tions of normal sera. Migration is
from bottom to top .
found after introducing substitution on the second galactose, such as in Galal-
3(Fucal-2)Gal (Table II) .
The antibody reaction was also inhibited by monosaccharides with galactose
being distinctly more active (50% inhibition at -10mM) than glucose, mannose,
and N-acetylhexosamines . A distinct increase of galactose inhibitory activity was
observed after methylation in a- but not in ,8-glycosidic linkage (Table 11).
The specific recognition of carbohydrate structures by the patient antibodies
suggests that the adsorption of tissue-reacting antibodies by erythrocytes (3, 11-
13) is due to similar surface epitopes . By using RIAs we found that the adsorption
of sera with rabbit and sheep but not with human erythrocytes reduced laminin
binding of patient sera to background values (Table I) . Reactive components
were detected in two fractions enriched for short or long carbohydrate chains of
purified neutral glycosphingolipids prepared from rabbit erythrocyte plasma
membranes . These components were separated by TLC and, after blotting,
reacted with patient and monkey antisera . The only stained band observed in
the short chain fraction (Fig . 4, B) corresponded to a glycosphingolipid with five
monosaccharide units, asjudged from its mobility . It very likely corresponds to
Gala 1-3Gal#1-4G1cNAc,l31-3Gal#1-4Glc-ceramide identified and characterized
in previous studies (36, 37) . The mobility of the reacting, slow-migrating band
of the long chain fraction (Fig . 4A) is compatible with an I and B blood group,
active branched ceramide decasaccharide with two terminal a-galactose residues
(38).
Specificity of Laminin-binding Antibodies from Normal Human Sera.
￿
Natural
antibodies with Galal-3Gal specificity have been previously described (17, 18)
to be ubiquitous in normal human sera implying that the normal laminin-binding
antibodies (Fig . 1) are identical . The specificity of the reaction of normal sera42 6
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Comparison of the a-galactose
epitope on mouse laminin with human
blood group substances by radioimmuno-
inhibition assay. The assay consisted of'25I-
labeled mouse laminin and serum from a
monkey infected with T. rhodesiense (a) or
normal human serum (b). Inhibitors used in
the assay were laminin (A), saliva blood
group substances A (p), B (O), 0 (p) before
and after (A, /; B, 0; 0, ") removal of
fucose by TCA hydrolysis. Inhibitorconcen-
trations are expressed as carbohydrate
equivalents, which were determined by an
orcinol assay.
with laminin was therefore determined by inhibition assays and showed no
substantial difference to the patterns found with patient and monkey antibodies.
The natural antibodies exhibited a similar crossreaction with various basement
membrane proteins that could be blocked most efficiently with Galal-3Ga1
disaccharide (Table 11), and the epitopes on laminin were found to be sensitive
to treatment with periodate and a-galactosidase (Fig. 3a). Some differences in
the fine specificity of natural and patient antibodies may exist as illustrated in
Fig. 3, a and b, and Table 11. The structural basis of such differences needs
further exploration.
Search for the Presence of Galal-3Gal Epitopes on Human Antigens.
￿
Laminin
was purified from human placenta but was 100-200-fold less active in inhibition
assays with normal and patient sera than mouse laminin. Its low activity was
identical to that of mouse laminin treated with a-galactosidase (Fig. 3, a and b) .
The residual activity may represent distinct epitopes since no activity was detected
with another human glycoprotein, fibronectin. Presumably, such activity could
be due to small amounts of a-galactose or reflect a weak crossreaction with
related carbohydrate structures present on human laminin. A comparably higher
inhibitor activity, equivalent to 50 )ug/ml of mouse laminin, was found in
conditioned medium of some human tumor cell lines (Fig. 3c) and some activity
was also produced by cultured embryonic fibroblasts . Since these media contain
a maximum of 1-2 mg/ml of laminin as determined by a specific RIA for human
placenta laminin, it indicates that the epitope may also be present on other
secreted products.
The terminal immunodominant structure of human B blood group substance
(39), Gala l-3(FucaI-2)Gal, shows some similarity to the epitope characterized
here but has a low affinity for the antibodies, as shown in erythrocyte adsorption
tests (Table I) and inhibition assays with salivary blood group substances (Fig. 5).
Defucosylation of the B substance by TCA hydrolysis (29) generated a highly
active inhibitor of laminin binding to normal and patient antibodies. Little or no
activity was found in defucosylated A and O substance (Fig. 5). This indicates
the potential for an efficient generation of terminal Galal-3Ga1 structures in
various components by a portion of the human population.
A comparison of Galal-3Gal with Gala l-3(Fuca1-2)Gal inhibitors that corre-
spond to the terminal structures of defucosylated and nonmodified human B
blood group substance, respectively, demonstrated a 10-600-fold difference inTOWBIN ET AL.
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inhibitory activity depending on the human serum used (Table I1). All the sera
examined contained anti-A and -B antibodies, indicating that the individuals lack
A and B blood group substances. Therefore, the variation in inhibitory potency
ofthe B epitope seemsnotto be related torecent observations (19)thatantibodies
from B+ persons exhibit a narrower recognition ofthe Galal-3Gal epitope than
those lacking the B phenotype.
Discussion
The data presented here demonstrate that laminin-binding antibodies identi-
fied previously in patients and monkeys infected with Trypanosoma (6, 9) and
Leishmania parasites (9) recognize oligosaccharide epitopes present on mouse
laminin. This was shown most definitely in inhibition studies with oligosaccha-
rides, which indicated that terminal Galal-3Gal residues are likely to be the
structures involved in the reaction . The carbohydrate nature of epitopes was
additionally shown by their destructionaftertreating lamininwith a-galactosidase
and periodate but not by alkali, pronase, or the reduction of disulfide bonds.
The antibodies also crossreacted with rabbit erythrocytes involvinga glycosphin-
golipid with a terminal Galal-3Gal structure (36, 37) and with an identical
sequence produced from human blood group B substance by defucosylation.
A comparison of various mono- and oligosaccharides as inhibitors (Table 11)
showed that terminal galactose in a(l-3) linkage to a second galactose contributes
most significantly to the antigenic specificity of the epitope. The penultimate
galactose is apparently also recognized by the antibodies, since the substitution
ofan additional fucose residue, such as that occurring in B blood group substance,
substantially reduces its affinity. Whether the disaccharide Galal-3Gal composes
the entire epitope is unknown. However, there is a strikingly lower inhibition by
the disaccharide compared with laminin, although similar differences between
macromolecular blood group substances and small carbohydrate haptens have
been noted before (39). Presumably, polymeric carbohydrate antigens can inter-
act simultaneously with both antibody binding sites increasing their affinity and
indicating that mouse laminin possesses several a-galactose epitopes.
The presence of some 50-60 residues of a-galactose on mouse laminin was
indicated in binding studies with Griffonia simplicifolia 1-B4 lectin (33, 34, 40)
and by degradation with a-galactosidase (33, 35). Several a-galactose containing
N-linked oligosaccharides have been isolated from laminin and found to contain
terminal Galal-?Gal structures (35). The same structures are also likely to be
present on other murine basement membrane proteins and on bovine laminin B
chains (Fig. 2). However, terminal a-galactose residues are not restricted to
basement membrane proteins and are found, for example, on erythrocytes (41)
and thyroglobulin (40) in several species.
Natural antibodies with Galal-3Ga1 specificity are present in all adult human
sera and have been previously detected (17, 18) by affinity chromatography on
Galal-6Glc, by rabbit erythrocyte agglutination and rosette tests. As shown here,
these antibodies react in RIAs with mouse laminin but with 10-100-fold lower
titers than those in patient and monkey sera. These natural antibodies, however,
closely correspond with those arising after parasitic infections in terms of their
disaccharide specificity and reaction with rabbit glycosphingolipids (reference428
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18; Fig. 4). Other antibody reactions reported for normal human sera and mouse
laminin (10, 42) are therefore very likely due to the same antibodies.
The identification ofthe carbohydrate nature ofcrossreacting laminin epitopes
also leaves little doubt that the antibodies arising after parasitic infections are
triggered by Galal-3Ga1 or similar epitopes present on glycolipids or glycopro-
teins of Trypanosoma and Leishmania parasites, since tissue-reacting antibodies
can be adsorbed with parasites (reviewed in reference 11) and such antibodies
purified by laminin immunoadsorption react strongly with various forms of T.
cruzi (6). It appears unlikely that the same stimuli are responsible for generating
the natural antibodies, particularly in Caucasian populations that are normally
not exposed to these parasites. As discussed elsewhere, for the generation of
natural antibodies against blood group substances (17, 39, 43) they may be
stimulated by antigens of the intestinal flora, diet, or by other infections. Anti-
basement membrane antibodies that react with mouse laminin in individuals with
poststreptococcal glomerulonephritis (10), preeclampsia (44), and mercury ex-
posure (45) could be related to the carbohydrate-specific antibodies defined here
and may have some bearing on the etiology ofthese conditions.
The ubiquitous occurence of the antibody response to Galal-3Gal structures,
augmented in certain diseases, indicates that this is a lack of immune tolerance
to these epitopes in the human species (41). Indeed, most data show the lack of
terminal a-galactose structures in human tissues as studied by specific lectin
binding of tissues (46), glomerular basement membrane proteins (47), and
thyroglobulin (40). Our antibody binding data agree with these observations by
showing their absence on human fibronectin and a low reactivity and presumed
content on human placenta laminin. This could be due to the absence or low
activity ofan a-galactosyl transferase as present in rabbit tissue, producing an a
1-3-linkage to another galactose residue. Two enzymes produce this structure by
using either Fucal-2Gal (resulting in B group structure) or a terminal galactose
as substrate (48). The latter transferase, which would generate the Galal-3Gal
epitope, has not been detected in human tissues, although its possible existence
was indicated in glial cells ofa Tay-Sachs embryo (49).
Some other data, however, indicate that terminal a-galactose groups, and
possibly Galal-3Gal epitopes, may exist in some normal or pathological human
tissues. This was demonstrated by lectin binding to some extracellular structures
ofperipheral nerves (50), which is ofparticular interest in view ofmAb reactions
with neurones and T. cruzi (14) and the occurence of nerve injury as a late
complication in Chagas disease (7). Such epitopes apparently also appear on
senescent, thalassemic (17, 18) and sickle cell erythrocytes (51), and various
human tumors (52, 53). Our data extend these observations by demonstrating
the epitope on various other tumor cell products and tissues.
Given the existence ofantibodies specific for the Galal-3Ga1 epitope during
normal life (17) and modulation oftheirlevels byinfections,a varietyofsituations
may arise that generate the epitope at certain stages ofaging or as a consequence
of pathological alterations. These may then be exposed to specific antibodies
raised before by foreign antigenic stimuli. Such situations could include the
removal ofaltered erythrocytes considered to be a physiological process (17, 18,
51). In some parasitic diseases it may include altered cells (macrophages, muscleWe appreciated helpful comments by Dr. George R. Martin and the skilled technical
assistance by Mrs. Hildegard Reiter and Vera van Delden. We also wish to thank Drs. J.
Convit and G. A. Maeckelt for kindly providing some leishmaniasic and chagasic sera.
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cells) which, due to the intracellular residence of parasites, may change their
surface structure by inserting parasite-derived epitopes (1) or changing host
componentsby new posttranslational modifications. Theautoimmunity observed
in Chagas disease may therefore not be to cross reacting structures (7, 11, 16)
present per se, but to a modified structure arising in the infected individuals.
Comparable expressions of new carbohydrate epitopes have been observed in
cancer cells (54), including antibodies to a-galactose epitopes in patients with
malignant ovarian germ cell tumors (55). Such modifications of the normal
repertoire of glycosylation reactions may be common sequelae of a variety of
degenerative conditions .
Summary
Sera from patients with American cutaneous leishmaniasis and Chagas disease
and from monkeys infected with either Trypanosoma cruzi or Trypanosoma rho-
desiense show, in RIAs, strong binding to mouse laminin. A distinct although
weaker binding activity is also detected in normal human sera. The antibodies
recognize a common carbohydrate epitope present on mouse laminin, which was
assigned to a terminal galactosyl(al-3)-galactose group. Distinct crossreactions
were observed with some other basement membrane proteins, rabbit glycosphin-
golipids, defucosylated human B blood group substance and components pro-
duced by some human tumor cells. Only little activity was, however, found on
laminin obtained from human placenta. The data indicate that the antibodies
arising in infectious diseases are stimulated by similar carbohydrate epitopes
present on the surface of parasites. Tissue-specific occurrence of such epitopes
may exist and explain the involvement of distinct tissues in autoimmune disor-
ders.
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